A Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Pediatric Patients with X-linked Hypophosphatemic Rickets/Osteomalacia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Burosumab (Primary)
- Indications Osteomalacia; X-linked dominant hypophosphataemic rickets
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 10 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2017 Status changed from not yet recruiting to recruiting.
- 21 Jun 2017 New trial record